Nektar Therapeutics (NKTR)
NASDAQ: NKTR
· Real-Time Price · USD
27.43
0.17 (0.62%)
At close: Aug 18, 2025, 3:59 PM
27.00
-1.57%
Pre-market: Aug 19, 2025, 05:34 AM EDT
0.62% (1D)
| Bid | 26.7 |
| Market Cap | 521.68M |
| Revenue (ttm) | 87.25M |
| Net Income (ttm) | -133.04M |
| EPS (ttm) | -8.64 |
| PE Ratio (ttm) | -3.17 |
| Forward PE | -1.87 |
| Analyst | Strong Buy |
| Ask | 28.5 |
| Volume | 630,729 |
| Avg. Volume (20D) | 1,925,625 |
| Open | 27.25 |
| Previous Close | 27.26 |
| Day's Range | 26.62 - 28.13 |
| 52-Week Range | 6.45 - 37.38 |
| Beta | 0.96 |
About NKTR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NKTR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NKTR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Nektar Therapeutics is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+156.29%
Nektar Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
+12.1%
Nektar Therapeutics shares are trading higher after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin on June 24, 2025.
1 week ago · fool.com
Nektar (NKTR) Q2 Revenue Falls 52%Nektar (NKTR) Q2 Revenue Falls 52%
1 month ago · seekingalpha.com
Nektar Therapeutics Scores Big Phase 2b Win With RezpegNektar Therapeutics Scores Big Phase 2b Win With Rezpeg